Printer Friendly
The Free Library
14,496,683 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Shionogi Launches New Quinolone Antibacterial "Avelox(R) Tablet 400mg" (Moxifloxacin Hydrochloride).


Tokyo, Japan, Dec 9, 2005 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
 Newswire) - Shionogi & Co., Ltd. (TSE See Tokyo Stock Exchange.

TSE

1. See Tokyo Stock Exchange (TSE).

2. See Toronto Stock Exchange (TSE).
: 4507) today announced the Japan launch of "Avelox(R) Tablet 400mg (moxifloxacin hydrochloride moxifloxacin hydrochloride

Avelox, Vigamox

Pharmacologic class: Fluoroquinolone

Therapeutic class: Anti-infective

Pregnancy risk category C

Action

), a new quinolone antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this.

an·ti·bac·te·ri·al
adj.
 licensed from Bayer Yakuhin, Ltd. (Head Office: Osaka) Avelox(R) Tablet, a respiratory quinolone, was developed by Bayer HealthCare AG. It has demonstrated an excellent antibacterial effect on all the major bacterial causes of respiratory tract infections Noun 1. respiratory tract infection - any infection of the respiratory tract
respiratory infection

infection - the pathological state resulting from the invasion of the body by pathogenic microorganisms
. First approved in 1999 in Europe and the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , this agent has been used to date to treat more than 40 million patients in 85 countries over its full range of indications.

Bayer Yakuhin and Shionogi reached an agreement in October 2003, under which Bayer Yakuhin granted exclusive Japanese marketing rights for Avelox(R) Tablet to Shionogi. In accordance Accordance is Bible Study Software for Macintosh developed by OakTree Software, Inc.[]

As well as a standalone program, it is the base software packaged by Zondervan in their Bible Study suites for Macintosh.
 with the agreement, Bayer Yakuhin acquired import approval on October 11, 2005 and upon obtaining National Health Insurance price listing today, Shionogi immediately launched the product and commenced domestic marketing on an exclusive

basis.

In order to facilitate the rapid penetration of Avelox(R) Tablet into the Japanese market, both companies will continue to work closely together in the areas of marketing and postmarketing surveillance Postmarketing surveillance is the practice of monitoring a pharmeceutical drug or device after it has been released on the market. Since drugs are approved on the basis of clinical trials which involve relatively small numbers of people who have been "controlled" for--meaning they .

Avelox(R) Tablet 400mg Product Summary
Product name:                     Avelox(R) Tablet 400mg
Generic name:                     Moxifloxacin hydrochloride
Acquisition of import approval:   October 11, 2005
NHI drug price listing:           December 9, 2005
Date of market launch:            December 9, 2005
Main characteristics:             Expected to have significant clinical
                                  efficacy as a respiratory quinolone because
                                  of its excellent antibacterial effect on
                                  all the major bacterial causes of
                                  respiratory tract infections and good
                                  migration to all tissues in the respiratory
                                  tract.
NHI drug price:                   544.40 yen for one 400mg tablet
                                  (Daily drug cost of 544.40 yen)


About Bayer HealthCare AG

Bayer HealthCare AG, a subsidiary of Bayer AG Bayer AG

German chemical and pharmaceutical company. Founded in 1863 by Friedrich Bayer (1825–1880), it now operates plants in more than 30 countries. Bayer has originated scores of pharmaceuticals, chemicals, and synthetic materials; it was the first developer and
, is one of the world's leading, innovative companies in the health care and medical products industry. In 2004, the Bayer HealthCare subgroup sub·group  
n.
1. A distinct group within a group; a subdivision of a group.

2. A subordinate group.

3. Mathematics A group that is a subset of a group.

tr.v.
 generated sales amounting to some 8.5 billion Euro. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in 2004. Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease. Visit: www.bayerhealthcare.com and http://www.cardio Cardio is the medical term used to reference the heart. From Greek kardia: heart. The Greek spelling using k is the reason for the usage of K in EKG (electrocardiogram). .bayer.com

About Bayer Yakuhin Ltd. (Osaka, Japan)

Bayer Yakuhin Ltd. is in charge of Japanese health care markets as a part of the global operations Global Operations is a first-person shooter computer game developed by Barking Dog Studios and published by both Crave Entertainment and Electronic Arts. It was released in March of 2002, following its public multiplayer beta version which contained only the Quebec map.  of Bayer HealthCare AG. The company employs 1,500 staff and develops pharmaceutical, consumer care and biological products. Bayer Yakuhin has set itself the challenge to build a customer focused health care company that significantly contributes to human health by encouraging innovation and creativity. Home Page: http://www.bayer.co.jp/byl/index.html

About Shionogi and Co., Ltd.

Shionogi & Co., Ltd, established in 1887 and was incorporated in 1919, is a major research-driven Japanese pharmaceutical manufacturer. The company's primary businesses are research and development, manufacturing, marketing, and import and export sales of pharmaceutical and diagnostics products. Shionogi follows a basic policy of continually providing the superior medicines essential to people's health. For more details, please visit http://www.shionogi.co.jp

Source: Shionogi and Co., Ltd.

Contact:
Bayer Yakuhin, Ltd.
Communications Department
Fujita Shimazaki
TEL: + 81-6-6398-1036
FAX: + 81-6-6398-1033

Shionogi & Co., Ltd.,
Public Relations Unit
Osaka TEL: +81-6-6209-7885
FAX: +81-6-6229-9596
Tokyo TEL: +81-3-3406-8164
FAX: +81-3-3406-8099


Copyright [c] 2005 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Geographic Code:4EUGE
Date:Dec 10, 2005
Words:592
Previous Article:WebKeepers Launches Plesk-Based Shared Web Hosting Service; Features English, Spanish and Japanese Support, Free Domain Registration.
Next Article:Yamaha's Design Studio London Opens Its Doors.



Related Articles
AVELOX, FAST-ACTING ANTIBIOTIC, APPROVED IN CANADA.
Antimicrobial drug-resistant Salmonella Typhimurium (Reply to Helms).(Letters)
Factors influencing fluoroquinolone resistance.(Letters)(Letter to the Editor)
Quinolone safety and efficacy more important than potency.(Letters)(Letter to the Editor)
Quinolone safety and efficacy.(LETTERS)(Letter to the Editor)
Toyama Chemical, NIDEK Receive Manufacturing Approval for New-quinolone Ophthalmic Solutions.
Toyama Chemical Licenses Quinolone-type Synthetic Antibacterial Agent, T-3811, to Dong-A Pharmaceutical.
Otsuka Pharmaceutical Releases New Quinolone Antibiotic Eyedrops.
Shionogi Obtains Manufacturing, Marketing Approval for OXINORM Powder 0.5%.
Shionogi Launches Cancer Pain Analgesic OxiNorm Powder 0.5% in Japan.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles